Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 0

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study

Passeron, Thierry, Lebwohl, Mark, Lynde, Charles, Alam, Maryam Shayesteh, Laquer, Vivian T., Beecker, Jennifer, Ganesan, Anand K., Timmers, Cynthia, Volkova, Angelina, Soltanalizadeh, Babak, Kornacki, Deanna, Smith, Susan H.·2026·Journal of Investigative Dermatology
DOI 10.1016/j.jid.2026.09.857
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jid.2026.09.857

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 24

  1. Bankhead, 2017, QuPath: Open source software for digital pathology image analysis, Sci Rep, 7, 10.1038/s41598-017-17204-5 · DOI · Paper page
  2. Bergqvist, 2020, Vitiligo: a review, Dermatology, 236, 571, 10.1159/000506103 · DOI · Paper page
  3. Bibeau, 2022, Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA, J Eur Acad Dermatol Venereol, 36, 1831, 10.1111/jdv.18257 · DOI · Paper page
  4. El-Domyati, 2022, Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome, Arch Dermatol Res, 314, 275, 10.1007/s00403-021-02228-9 · doi:10.1007/s00403-021-02228-9
  5. Eleftheriadou, 2024, Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK, Br J Dermatol, 191, 216, 10.1093/bjd/ljae133 · DOI · Paper page
  6. Esmat, 2012, Acral lesions of vitiligo: why are they resistant to photochemotherapy?, J Eur Acad Dermatol Venereol, 26, 1097, 10.1111/j.1468-3083.2011.04215.x · DOI
  7. Hamzavi, 2004, Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index, Arch Dermatol, 140, 677, 10.1001/archderm.140.6.677 · DOI · Paper page
  8. Harris, 2012, A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8+ T-cell accumulation in the skin, J Invest Dermatol, 132, 1869, 10.1038/jid.2011.463 · DOI · Paper page
  9. Harris, 2024, Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: a randomised controlled trial secondary analysis at 3 years, Skin Health Dis, 4, 10.1002/ski2.404 · DOI
  10. Howell, 2023, Baseline levels of circulating inflammatory biomarkers stratify patients with vitiligo who significantly repigment after treatment with ruxolitinib cream, JID Innov, 3, 10.1016/j.xjidi.2023.100230 · DOI
  11. Hu, 2023, Beyond skin white spots: vitiligo and associated comorbidities, Front Med (Lausanne), 10
  12. Liberzon, 2015, The Molecular Signatures Database (MSigDB) hallmark gene set collection, Cell Syst, 1, 417, 10.1016/j.cels.2015.12.004 · DOI · Paper page
  13. Liu, 2024, The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment, Eur J Immunol, 54, 10.1002/eji.202250281 · DOI
  14. Maouia, 2017, Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients, Pigment Cell Melanoma Res, 30, 259, 10.1111/pcmr.12559 · DOI
  15. Passeron, 2024, Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeks, J Eur Acad Dermatol Venereol, 39, e251
  16. Persaud, 2020, Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs, Int J Pharm, 590, 10.1016/j.ijpharm.2020.119889 · DOI
  17. Rashighi, 2014, CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo, Sci Transl Med, 6, 10.1126/scitranslmed.3007811 · DOI · Paper page
  18. Rashighi, 2015, Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo, Ann Transl Med, 3, 343
  19. Rashighi, 2016, Serum chemokines herald disease activity and treatment response in vitiligo patients, Br J Dermatol, 174, 1190, 10.1111/bjd.14671 · DOI
  20. Rosmarin, 2020, Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial, Lancet, 396, 110, 10.1016/S0140-6736(20)30609-7 · DOI · Paper page
  21. Rosmarin, 2022, Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo, N Engl J Med, 387, 1445, 10.1056/NEJMoa2118828 · DOI · Paper page
  22. Seneschal, 2023, Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force-part 2: specific treatment recommendations, J Eur Acad Dermatol Venereol, 37, 2185, 10.1111/jdv.19450 · doi:10.1111/jdv.19450
  23. van den Boorn, 2009, Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients, J Invest Dermatol, 129, 2220, 10.1038/jid.2009.32 · DOI · Paper page
  24. Wang, 2016, Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo, Br J Dermatol, 174, 1318, 10.1111/bjd.14416 · DOI · Paper page

Metadata

Authors
Passeron, T., Lebwohl, M., Lynde, C., Alam, M. S., Laquer, V. T., Beecker, J., Ganesan, A. K., Timmers, C., Volkova, A., Soltanalizadeh, B., Kornacki, D., & Smith, S. H.
Venue
Journal of Investigative Dermatology
Publisher
Elsevier BV
Published
2026-10
ISSN
0022-202X
DOI
10.1016/j.jid.2026.09.857
Cited by
0
References
1
Language
en
Licence
Funders
Incyte

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study. https://app.cochat.ai/papers/10.1016/j.jid.2026.09.857
The paper
Passeron, T., Lebwohl, M., Lynde, C., Alam, M. S., Laquer, V. T., Beecker, J., Ganesan, A. K., Timmers, C., Volkova, A., Soltanalizadeh, B., Kornacki, D., & Smith, S. H. (2026). Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.09.857

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.